Godrej AgrovetQ1 FY27
Godrej Agrovet Q1 FY27 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Price: ₹609P/E: 23.6Market Cap: ₹11.1K CrSector: Food Products
Management growth scorecard
Revenue
Category 3
Margin
Category 3
Fundraise
N/A
Order
N/A
Capex
Yes
1 of 3 growth signals are positive — mixed outlook.
Full analysisRevenue guidance
Category 3- →Oil Palm Business: Expected high single-digit to early double-digit FFB (Fresh Fruit Bunch) volume growth over the next 3-5 years due to area expansion and multiple growth pillars.
- →Crop Care Business: Anticipated double-digit growth in revenues, with new product launches (Ashitaka, Takai, Ghassnash) gaining market traction, though short-term impact from delayed monsoon persists.
- →Animal Nutrition Business: Fish feed growing at 20%+, cattle feed dominating with 55-56% share and growing at 15%. Non-cattle feeds growing healthily with focus on profitable geographies and premiumization.
- →Dairy Business: Experiencing volume growth in value-added products, aiming for portfolio premiumization and route-to-market transformation for improved profitability.
- →Godrej Foods: Branded volumes growing (~6%) with Yummiez up 22%, focusing on building a higher-quality branded foods portfolio.
- →Bangladesh JV (ACI Godrej): Returning to strong double-digit volume, revenue, and profitability growth.
- →Overall, Godrej Agrovet targets sustainable double-digit growth, with clearer guidance expected by Q2 FY27 end.
Margin guidance
Category 3- →**Animal Nutrition:** Expect continued volume growth (~7%), with stable EBIT per tonne guidance around INR 2,050-2,150 supported by premiumization and geographic expansion.
- →**Oil Palm:** Anticipated high single-digit to early double-digit FFB volume growth over 3-5 years; EBITDA expected to grow beyond INR 500 crores with integrated value-added downstream expansion contributing an estimated 200 bps to overall EBITDA margin.
- →**Crop Care:** Recovery expected in H2 FY27 after a slow start due to delayed monsoon; guidance on segment revenue outlook to be clearer by end of Q2; portfolio diversification with new product launches supports growth.
- →**Astec LifeSciences:** Confident of over 20% revenue growth for FY27 with margin normalization and operational recovery continuing.
- →**Overall:** Management targets double-digit consolidated sales and PBT growth for FY27, with clearer visibility post Q2.
3 more insights locked — sign up free to unlock
Fundraise plans
- →There is no explicit mention of any current or future new fundraising through debt or equity in the provided transcript pages.
- →The company has discussed capex guidance, with a planned investment of around INR 300-350 crores already assumed in their business plans, indicating no new capital raising is anticipated for this purpose.
- →Capex investments include integrated complex and specialty investments aiming for high IRR (around 16%-18%).
- →Focus remains on capital allocation discipline and balance sheet efficiency, with improvements in net working capital and cash generation highlighted.
- →No references to upcoming equity issuance or debt raising were made in the discussions on business growth, expansions, or strategic plans.
Order book
The transcript does not explicitly mention current or expected order book or pending orders for Godrej Agrovet Limited. However, some related insights include:
- CDMO segment: Orders and discussions are ongoing; some demand shifted from H1 to H2, indicating active order pipeline.
- Crop Care business: New product launches and segment diversification underway, suggesting future order inflows.
- Palm oil and animal nutrition segments: Expansion and volume growth expected, implying growing business demand.
- Overall outlook: Management expresses confidence in double-digit growth for the year with positive demand outlook in latter half.
No concrete figures or specific order book details were disclosed in the provided transcript.
Capex plans
Yes- →Godrej Agrovet has planned overall capex of around INR 300-350 crores at the business level, which includes ongoing and planned investments.
- →Key ongoing investments include:
- → - Integrated complex with the first phase kicked off this year.
- → - Specialty fats factory starting early ramp-up in the second half of the year.
- → - Upcoming refinery of specialty fats slated for rollout by end August/early September.
- → - Seed garden for future genetic work expected within 18-24 months.
- →Capex is planned in phases over 3-4 quarters and is assumed in current guidance.
- →The company targets a high IRR (16-18%) from these investments.
- →These capex projects aim to transform the oil palm business into a full integrated upstream-to-downstream value-added business, including specialty food ingredients.
- →No additional or unplanned capex beyond the guidance has been indicated.
How does Godrej Agrovet rank vs peers in Food Products?
Pro feature1Godrej Agrovet
Rev 3Mar 3
See full Food Products sector rankings
How does Godrej Agrovet rank in Food Products?
Compare Godrej Agrovet against every Food Products company (Q1 FY27) on revenue, margins and earnings-call signals.